14:50 EST Revolution Medicines (RVMD) near deal to be bought by AbbVie (ABBV), WSJ says
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines trading halted, volatility trading pause
- Erasca initiated with an Overweight at Piper Sandler
- Revolution Medicines price target raised to $98 from $82 at BofA
- Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Extending Long-Term Upside Potential
- These Are the Most and Least Likely Biotech Takeover Targets for 2026